falsefalse

Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024 - Episode 8

The Potential of Oral HMAs in MDS

,

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Dissecting the Current Treatment Landscape in MDS
    EP. 2: The Importance of Treating Anemia in MDS
    EP. 3: Optimal Goals for Anemia and Transfusion Independence in MDS
    EP. 4: Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS
    EP. 5: Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS
    EP. 6: Other Potential Roles for Luspatercept in MDS And Beyond
    EP. 7: Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS
    Now Viewing
    EP. 8: The Potential of Oral HMAs in MDS

    Related Content:

    Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024The University of Texas MD Anderson Cancer CenterYale Cancer CenterMyeloproliferative NeoplasmsOncLive News Network®
    Dr Morris on the FDA Approval of Nivolumab/Ipilimumab for dMMR/MSI-H Metastatic CRC
    Encorafenib/Cetuximab Plus mFOLFOX6 Provides New SOC for BRAF V600E+ mCRC
    Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis
    x